HopeStage
Back to all studies
CompletedNCT00159770

Ziprasidone compared with other antipsychotic medicines in schizophrenia

About this titleRead the official source — NCT00159770
Medication studyAges 18+Multiple countries
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Aalborg and 42 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateNovember 2001
Recruitment status
Completed
Enrollment listed in the registry
290
Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Behavioural, Drug, Procedure
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Switzerland, Denmark, Finland, ...
Age range
Over 18 Years
Official registry ID
NCT00159770
Official title
Show the full official title

Tolerability, Safety, And Efficacy Of Ziprasidone (80 - 160 Mg/D) Versus Olanzapine (10 - 20 Mg/D), Risperidone (4 - 8 Mg/D) Or Quetiapine (300 - 750 Mg/D) In Pretreated Patients With Schizophrenia, Schizoaffective Disorder Or Schizophreniform Disorders - A 12-Week Open-Label, Multicenter Clinical Trial.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Aalborg, Denmark · Arhus C, Denmark · Augustenborg, Denmark

40 more locations
  • Ballerup Municipality, Denmark
  • Brovst, Denmark
  • Copenhagen, Denmark
  • Dianalund, Denmark
  • Esbjerg, Denmark
  • Esbjerg N, Denmark
  • Glostrup Municipality, Denmark
  • Haderslev, Denmark
  • Holbæk, Denmark
  • Kjellerup, Denmark
  • Kolding, Denmark
  • København S, Denmark
  • Lemvig, Denmark
  • Odense C, Denmark
  • Ringkøbing, Denmark
  • Risskov, Denmark
  • Vejle, Denmark
  • Viborg, Denmark
  • Vordingborg, Denmark
  • Forssa, Finland
  • Helsinki, Finland
  • Jarvenpaa, Finland
  • Kiviranta, Finland
  • Mikkeli, Finland
  • Turku, Finland
  • Tuusula, Finland
  • Reykjavik, Iceland
  • Basel, Switzerland
  • Bern, Switzerland
  • Sankt Gallen, Switzerland
  • Lausanne, Switzerland
  • Prangins, Switzerland
  • Zurich, Switzerland
  • Bulle, Switzerland
  • Chêne-Bourg, Switzerland
  • Delémont, Switzerland
  • Oetwil, Switzerland
  • Riehen, Switzerland
  • Saint Urban, Switzerland
  • Solothurn, Switzerland

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Did this study involve medication?

Yes. The study involved medication, including ziprasidone versus olanzapine , risperidone or quetiapine.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies